Schall Law investigates Grace Therapeutics after FDA rejection
The Schall Law Firm has launched an investigation into Grace Therapeutics concerning potential securities law violations. The probe follows a 45.5% drop in share price after the FDA issued a Complete Response Letter for the company's GTx-104 drug application, citing manufacturing and toxicology issues.
*this image is generated using AI for illustrative purposes only.
The Schall Law Firm is investigating Grace Therapeutics on behalf of investors regarding potential violations of securities laws. The investigation focuses on whether the company issued false or misleading statements or failed to disclose pertinent information. This legal scrutiny follows a significant regulatory setback that impacted shareholder value.
Grace Therapeutics announced on April 23, 2026, that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for GTx-104. The treatment is intended for patients with aSAH. The FDA cited specific deficiencies in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of the application.
The regulatory body identified issues related to leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at the company's contract manufacturing organization. Following this announcement, shares of Grace fell by nearly 45.5% on the same day.
Key Regulatory Developments
The investigation centers on the timeline and accuracy of disclosures surrounding the FDA's decision. The Complete Response Letter highlighted specific areas of concern that the company must address before the application can proceed.
| Aspect | Details |
|---|---|
| Drug | GTx-104 |
| Indication | Treatment of patients with aSAH |
| FDA Action | Complete Response Letter (CRL) |
| Date of Announcement | April 23, 2026 |
| Cited Issues | CMC and Non-Clinical sections |
| Specific Deficiencies | Leachables data, toxicology risk assessments, manufacturing deficiencies |
The Schall Law Firm, a national shareholder rights litigation firm, represents investors globally and specializes in securities class action lawsuits. Investors who suffered losses are encouraged to contact the firm to discuss their rights.
What is the estimated timeline for Grace Therapeutics to resolve the CMC and non-clinical deficiencies identified in the CRL?
How will the manufacturing deficiencies at the contract manufacturing organization impact the company's ability to scale production upon potential approval?
Does Grace Therapeutics have sufficient cash reserves to fund the additional studies and manufacturing fixes required by the FDA?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
